Welcome to our dedicated page for AETERNUM HEALTH SEC filings (Ticker: AETN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AETERNUM HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AETERNUM HEALTH's regulatory disclosures and financial reporting.
Aeternum Health, Inc. (AETN) obtained written consent from a stockholder controlling approximately 73% of the voting power (Paul Mann, Chairman and President) to approve several charter amendments without holding a meeting or soliciting proxies. No appraisal (dissenters’) rights are provided.
The company will change its name to Aeternum Resources, Inc., increase authorized common stock from 250,000,000 to 500,000,000, and effect a 1-for-20 reverse stock split of its common stock, reducing outstanding shares from 97,105,204 to about 4,855,261 (before rounding). The reverse split will not change par value or reduce authorized shares, increasing the pool of authorized but unissued shares.
The number of designated Series B Preferred Stock shares will rise from 2,000,000 to 4,000,000; each Series B share carries voting power equal to 40 common shares and may be used as consideration in transactions, including mineral projects. The amendments become effective no earlier than September 21, 2026 and also require FINRA announcement of the name change and reverse split.
Aeternum Health, Inc. (AETN) is shifting strategy and identity, changing its name to Aeternum Resources, Inc. and focusing on becoming a supplier of critical minerals, initially via a tin, niobium and tantalum project on the Jos Plateau in Nigeria. The company reports having raised over $4 million from Paul Mann through a promissory note to advance this project, which is expected to enter commercial production in 1H 2027.
Effective July 31, 2026, Paul E. Mann becomes President and Executive Chairman, and Josua Oosthuizen becomes Chief Executive Officer under a two-year employment agreement with a $240,000 base salary, annual bonus eligibility up to 60% of salary and up to $800,000 in milestone-based bonuses tied to achieving US GAAP-based average monthly revenues of $3 million, $6 million, $9 million and $12 million. Pieter Scholtz was appointed CFO under a two-year agreement with a $165,000 base salary and discretionary bonus eligibility.
The Nigerian project’s gravity separation plant is designed to process approximately 90 metric tonnes per hour, or about 500,000 metric tonnes per year, and is expected to be installed during 4Q 2026, with Phase 1 anticipated to run until February 2027. The board and shareholders approved an increase in authorized capital to 500,000,000 common shares and 10,000,000 blank check preferred shares, the exchange of $1,500,000 of debt into 75,000,000 common shares valued at $0.02 each, and a 1-for-20 reverse stock split with fractional shares rounded up.
Aeternum Health, Inc. (AETN) discloses that stockholders holding approximately 73% of the voting power, led by Chairman and President Paul Mann, have approved several charter amendments by written consent. The company will change its name to Aeternum Resources, Inc., reflecting a new focus that includes mining and processing critical minerals alongside its longevity and health-related business.
The charter amendments increase authorized common stock from 250,000,000 to 500,000,000 shares and authorize a 1‑for‑20 reverse stock split. Based on 97,105,204 common shares outstanding as of August 21, 2026, the reverse split would reduce issued and outstanding shares to approximately 4,855,261, while leaving par value and authorized share count unchanged, significantly expanding authorized but unissued capacity. Each share of Series B Preferred Stock carries the voting power of 40 common shares.
The company will also increase designated Series B Preferred Stock from 2,000,000 to 4,000,000 shares, intended for use as consideration in transactions, including resource projects. All existing 2,000,000 Series B shares are held by Paul Mann, who currently controls about 73% of total voting stock. The actions become effective at least 20 days after mailing the definitive information statement and after FINRA announces the name change and reverse split.
Aeternum Health, Inc. (AETN) completed a major transformation in the quarter ended June 30, 2026, closing the reverse-acquisition merger with Aeternum Health LLC, divesting its Shorepower transportation-electrification business, and refocusing on critical-mineral mining and longevity-focused healthcare. The Shorepower disposal generated a $2,037,315 gain and removed legacy liabilities.
Continuing operations generated no revenue and a loss from continuing operations of about $300,879 for the six months, driven by exploration, consulting and project-development costs. Despite reporting net income of $1,582,883 for the six months, cash use from operations was about $1.6 million, funded mainly by $2,270,348 in related-party notes from Paul Mann and small equity raises. Cash was $702,809 and working capital about $1.8 million as of June 30, 2026, but management disclosed substantial doubt about the company’s ability to continue as a going concern.
The company increased authorized common shares to 250 million and, after quarter-end, issued over 50 million new shares related to the merger and a finder’s fee, while Jeff Kim cancelled 6,630,000 shares. Aeternum also agreed to invest $10.0 million for a 50.1% interest in American Renaissance Minerals LLC’s Nkamouna nickel-cobalt project in Cameroon, contingent on permits and other conditions, which will require significant additional capital.
Aeternum Health, Inc. has agreed to issue 50,000,000 common shares and 2,000,000 Series B preferred shares to Manaslu LLC to acquire an option over a majority interest in American Renaissance Minerals, sponsor of the Nkamouna nickel‑cobalt‑manganese project in Cameroon.
Nkamouna is described as one of the largest undeveloped cobalt‑nickel‑manganese projects globally, with extensive historical technical work and a large mining area of approximately 1,650 km2. A historical mineral resource estimate of 323 million tonnes with specified cobalt, nickel and manganese grades is provided, but explicitly characterized as historical, not compliant with subpart 1300 of Regulation S‑K, and not treated as a current mineral resource.
Aeternum plans to contribute capital and engineering expertise, aiming to build a concentrator similar to its Nigerian plant and to supply traceable, responsibly produced critical minerals into United States and allied supply chains. The project is being advanced under Cameroon’s 2023 Mining Code, which includes a 10% free‑carried interest for the state.